Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma

Keyphrases

• Murine Model 100%
• Hepatocellular Carcinoma 100%
• Histone Deacetylase Inhibitor (HDACi) 100%
• Suberoylanilide Hydroxamic Acid 100%
• Tumor Xenograft 40%
• Therapeutic Strategies 20%
• Cancer Cell Survival 20%
• Antitumor Effect 20%
• Tumor Burden 20%
• Tumor Growth 20%
• In Vivo Model 20%
• B-cell Lymphoma 20%
• Oral Administration 20%
• Therapeutic Potential 20%
• Multiple Aspects 20%
• Antitumor Activity 20%
• Cancer Causes 20%
• Cancer Mortality 20%
• IC50 Value 20%
• In Vivo Efficacy 20%
• Survivin 20%
• Every Other Day 20%
• Huh7 Cells 20%
• Orally Bioavailable 20%
• Athymic nude Mice 20%
• Tumor Suppression 20%
• Xenograft Tumor Model 20%
• Start of Treatment 20%
• Apoptosis Regulation 20%
• Apoptogenic 20%
• Orthotopic Xenograft 20%
• Human Hepatocellular Carcinoma 20%
• Oral Treatment 20%
• Clinical Value 20%
• Phosphorylated Akt 20%
• Cellular Inhibitor of Apoptosis Protein 2 20%
• Cytokine-induced Apoptosis Inhibitor 1 20%
• Median Inhibitory Concentration 20%
• Apoptotic Regulator 20%
• Advanced Hepatocellular Carcinoma 20%
• Hep3B Cells 20%
• Phenylbutyrate 20%
• Large Tumors 20%
• Subcutaneous Xenograft 20%
• Ectopic Tumor 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Liver Cell Carcinoma 100%
• Histone Deacetylase Inhibitor 100%
• Vorinostat 100%
• Neoplasm 80%
• Histone Deacetylase 40%
• IC50 40%
• Biological Marker 20%
• Malignant Neoplasm 20%
• Tumor Growth 20%
• Nude Mouse 20%
• Survivin 20%
• Antitumor Activity 20%
• Tumor Model 20%
• B Cell Lymphoma 20%
• Cancer Mortality 20%
• Cancer Inhibition 20%
• Arylbutyric Acid Derivative 20%
• Baculoviral IAP Repeat Containing Protein 3 20%
• Inhibitor of Apoptosis Protein 2 20%
• Oral Administration 20%